title: New challenges for HDL-modifying therapies as a strategy to lower cardiovascular disease events in statin-treated patients.
authors.affiliation: Mount Sinai Heart, Mount Sinai Icahn School of Medicine, New York, NY, USA, robert.rosenson@mssm.edu.
authors.forename: Robert S
authors.initials: RS
authors.lastname: Rosenson
authors.forename: H Bryan
authors.initials: HB
authors.lastname: Brewer
mesh_terms: D064286:ATP Binding Cassette Transporter 1 / Q000378:metabolism*; D000818:Animals; D002784:Cholesterol / Q000378:metabolism*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D008075:Lipoproteins, HDL / Q000378:metabolism*; D035683:MicroRNAs / Q000378:metabolism*; D019821:Simvastatin / Q000494:pharmacology*
chemical_list: D064286:ATP Binding Cassette Transporter 1; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008075:Lipoproteins, HDL; D035683:MicroRNAs; D002784:Cholesterol; D019821:Simvastatin